Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aceclofenac + rabeprazole
- Development stage
- Unknown
- Lead developer
- Zeebharat Med Private Limited
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Aceboat Rz is a fixed-dose combination pharmaceutical product containing the non-steroidal anti-inflammatory drug (NSAID) aceclofenac and the proton pump inhibitor (PPI) rabeprazole sodium. Developed by Zeebharat Med Private Limited, this combination is primarily indicated for the management of pain and inflammation associated with musculoskeletal disorders such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. Aceclofenac works by inhibiting the cyclooxygenase enzymes (COX-1 and COX-2), which are responsible for the synthesis of inflammatory prostaglandins. The inclusion of rabeprazole sodium serves as a gastroprotective agent; it suppresses gastric acid secretion by irreversibly inhibiting the H+/K+-ATPase enzyme system (the proton pump) in gastric parietal cells. This dual-action approach allows for effective pain management while significantly reducing the risk of NSAID-induced gastric and duodenal ulcers.
- Brand names
- Aceboat Rz
- Other names
- Aceclofenac + Rabeprazole sodium
02
Targets
ATP4A (Potassium–transporting ATPase alpha chain 1)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on aceclofenac + rabeprazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aceclofenac + rabeprazole.